ストックスクリーナーアプリを入手
77.03
0.51%
-0.395
アフターアワーズ：
77.25
0.225
+0.29%
前日終値:
$77.42
開ける：
$77.05
24時間の取引高:
107.83K
Relative Volume:
0.36
時価総額：
$755.77M
収益：
-
当期純損益:
$-19.80M
株価収益率:
-31.53
EPS:
-2.4426
ネットキャッシュフロー:
$-14.56M
1週間 パフォーマンス:
-3.09%
1か月 パフォーマンス:
+7.98%
6か月 パフォーマンス:
-13.54%
1年 パフォーマンス:
+75.22%
1日の値動き範囲:
$74.44
$78.91
1週間の範囲:
$74.44
$87.00
52週間の値動き範囲:
$38.00
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Compare DRUG vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
77.03 | 770.84M | 0 | -19.80M | -14.56M | -2.4426 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-13 | 開始されました | Jefferies | Buy |
| 2025-09-08 | 開始されました | BTIG Research | Buy |
| 2025-05-13 | 開始されました | TD Cowen | Buy |
| 2025-05-07 | 開始されました | Chardan Capital Markets | Buy |
| 2025-01-23 | 開始されました | Piper Sandler | Overweight |
| 2025-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-01-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-26 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Bright Minds Biosciences Inc (DRUG) 最新ニュース
Wall Street Zen Upgrades Bright Minds Biosciences (NASDAQ:DRUG) to Hold - MarketBeat
Bright Minds Biosciences Stock Falls 4.60% as Investors Weigh BMB-101 Clinical Progress Against Biotech Development Risk - kalkine.ca
What is HC Wainwright's Forecast for DRUG FY2026 Earnings? - MarketBeat
Bright Minds Biosciences Slides as Biotech Volatility Returns — What Could Wake the Stock Up? - kalkine.ca
Bright Minds Biosciences Stock Faces Fresh Pressure — Can Clinical Momentum Offset Rising Correction Risk? - kalkine.ca
Psychedelic: Enveric, Helus, Bright Minds report earnings results - TipRanks
H.C. Wainwright reiterates Bright Minds stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Bright Minds stock rating at buy - Investing.com
Bright Minds Biosciences (NASDAQ:DRUG) Earns "Buy" Rating from HC Wainwright - MarketBeat
Bright Minds Biosciences Stock: An Epilepsy Story Keeps Drawing Biotech Money - kalkine.ca
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 5.9%Should You Buy? - MarketBeat
BTIG Research Reiterates "Buy" Rating for Bright Minds Biosciences (NASDAQ:DRUG) - MarketBeat
TD Cowen Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating - Moomoo
Liquidity Mapping Around (DRUG) Price Events - Stock Traders Daily
Bright Minds Biosciences (NASDAQ:DRUG) Issues Quarterly Earnings Results - MarketBeat
Bright Minds (DRUG) reports Phase 2 seizure gains in treatment‑resistant epilepsy - Stock Titan
Bright Minds Biosciences (DRUG): Cormorant Asset Management reports 9.17% ownership stake - Stock Titan
Bright Minds Biosciences (DRUG) Slips to $78.00 as Traders Eye Support at $74.1Chart Pattern Alerts - Vinanet
Can Bright Minds (TSX:DRUG) Keep Biotech Momentum Going? - Kalkine Media
Adage Capital (DRUG) discloses 3.41% Bright Minds Biosciences stake in latest holding - Stock Titan
Bright Minds Biosciences Inc. expected to post a loss of C$1.76 a shareEarnings Preview - TradingView
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet - finance.yahoo.com
Bright Minds Biosciences Inc (CN:DRUG) Shares Under Pressure as Biotech Sentiment Weakens and Development Risks Increase - kalkine.ca
Bright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal Trials (NASDAQ:DRUG) - Seeking Alpha
Bright Minds Biosciences (CN:DRUG): The Ticker Everyone's Talking About After a US$175M Raise and a Seizure Data Bombshell - kalkine.ca
Bright Minds Biosciences Inc (CN:DRUG) Jumps 4.05%: neuroscience biotech's Canadian line rose to C$114 on almost no volume, a thin-trading blip rather than - kalkine.ca
Bright Minds Biosciences (DRUG) to Post Quarterly Earnings on Thursday - MarketBeat
Why (DRUG) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Bright Minds Biosciences (DRUG) Holds Gains Above $73 as Bulls Eye $77.47 ResistanceIV Crush Alert - Vinanet
Perceptive Advisors LLC Sells 71,746 Shares of Bright Minds Biosciences Inc. $DRUG - MarketBeat
Janus Henderson Group PLC Raises Holdings in Bright Minds Biosciences Inc. $DRUG - MarketBeat
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
ADAR1 Capital Management LLC Has $2.47 Million Stock Position in Bright Minds Biosciences Inc. $DRUG - MarketBeat
Bright Minds Biosciences Inc (DRUG) Cash Flow - TradingKey
40,000 Shares in Bright Minds Biosciences Inc. $DRUG Acquired by Orbimed Advisors LLC - MarketBeat
Bright Minds Biosciences Inc (DRUG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bright Minds Biosciences Inc (DRUG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bright Minds Biosciences Inc (DRUG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bright Minds Biosciences Inc (DRUG) Institutional Confidence - TradingKey
DRUG|Bright Minds Biosciences Inc|Price:71.840|Chg%:+0.510 - TradingKey
Bright Minds Biosciences Inc (DRUG) Balance Sheet - TradingKey
Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High? - Yahoo Finance
Wall Street Analysts See a 27.16% Upside in Unity Software (U): Can the Stock Really Move This High? - Zacks Investment Research
Walleye Capital LLC Has $3.92 Million Holdings in Bright Minds Biosciences Inc. $DRUG - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Upgraded at Zacks Research - MarketBeat
All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy - Yahoo Finance
Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Bright Minds Biosciences (DRUG) Rallies 4.25% as Shares Approach Key ResistanceVolatility Breakout Picks - vinanet.vn
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 5%Should You Buy? - MarketBeat
Eli Lilly deal to buy AtaiBeckley (psychedelic) - KuCoin
Wall Street Analysts See a 27.35% Upside in Harmony Biosciences (HRMY): Can the Stock Really Move This High? - Yahoo Finance
Bright Minds Biosciences Inc (DRUG) 財務データ
収益
当期純利益
現金流量
EPS
0.00%
3.22%
大文字化:
|
ボリューム (24 時間):